Two Sigma Investments
AXSM icon

Two Sigma Investments’s Axsome Therapeutics AXSM Stock Holding History

Two Sigma Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$625K Buy
+3,700
New +$639K ﹤0.01% 3578

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's AXSM Position: Q1 2026 in Review

Two Sigma Investments increased its Axsome Therapeutics (AXSM) stake by 122% in Q1 2026, buying an estimated $30.6M and bringing the position to 322,778 shares worth $54.6M. The position accounts for 0.04% of the portfolio, ranked #467.

Two Sigma Investments first reported a position in AXSM in Q4 2020 and has held it in 10 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Two Sigma Investments held 322,778 shares of Axsome Therapeutics worth $54.6M as of Q1 2026.
  • Two Sigma Investments bought 177,181 Axsome Therapeutics shares in Q1 2026, an estimated $30.6M.
  • Axsome Therapeutics made up 0.04% of Two Sigma Investments's portfolio in Q1 2026, its #467 holding.
  • Two Sigma Investments first reported a position in Axsome Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.